Kamada (KMDA) Stock Price
Kamada Price
Revenue has compounded at 14.8% per year over the past 19 years to 180.46 M USD. Earnings per share have grown at 31.8% per year over the last 13 years. Kamada's net margin stands at 11.2%, up from -2.2% several years earlier. Kamada currently offers a dividend yield of about 2.41%. The payout ratio is around 61% of earnings. Analysts set a median price target of 13.00 USD, implying 56.4% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 26% above its 52-week low.
Kamada stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Kamada over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Kamada stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Kamada's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Kamada Price |
|---|---|
| 9/14/2026 | 8.31 USD |
| 9/11/2026 | 7.94 USD |
| 9/10/2026 | 7.99 USD |
| 9/9/2026 | 8.21 USD |
| 9/8/2026 | 8.24 USD |
| 9/4/2026 | 8.54 USD |
| 9/3/2026 | 8.27 USD |
| 9/2/2026 | 8.40 USD |
| 9/1/2026 | 8.38 USD |
| 8/31/2026 | 8.23 USD |
| 8/28/2026 | 8.30 USD |
| 8/27/2026 | 8.20 USD |
| 8/26/2026 | 8.38 USD |
| 8/25/2026 | 8.63 USD |
| 8/24/2026 | 8.49 USD |
| 8/21/2026 | 8.24 USD |
| 8/20/2026 | 8.02 USD |
| 8/19/2026 | 7.86 USD |
| 8/18/2026 | 7.69 USD |
| 8/14/2026 | 7.58 USD |
| 8/13/2026 | 7.26 USD |
| 8/12/2026 | 6.91 USD |
| 8/10/2026 | 7.14 USD |
| 8/7/2026 | 7.27 USD |
| 8/6/2026 | 7.14 USD |
| 8/5/2026 | 7.26 USD |
| 8/4/2026 | 7.34 USD |
| 8/3/2026 | 7.23 USD |
| 7/31/2026 | 7.14 USD |
| 7/30/2026 | 7.10 USD |
Kamada Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Kamada Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.00 | 70.00 | 71.00 | 70.00 | 77.00 | 102.00 | 114.00 | 127.00 | 133.00 | 103.00 | 129.00 | 142.00 | 160.00 | 180.00 | 604.00 | 670.00 |
| 30.91 | -2.78 | 1.43 | -1.41 | 10.00 | 32.47 | 11.76 | 11.40 | 4.72 | -22.56 | 25.24 | 10.08 | 12.68 | 12.50 | 235.56 | 10.93 |
| 30.56 | 37.14 | 21.13 | 22.86 | 27.27 | 31.37 | 35.96 | 38.58 | 35.34 | 29.13 | 35.66 | 38.73 | 43.13 | 42.22 | 42.22 | 42.22 |
| 22.00 | 26.00 | 15.00 | 16.00 | 21.00 | 32.00 | 41.00 | 49.00 | 47.00 | 30.00 | 46.00 | 55.00 | 69.00 | 76.00 | 255.02 | 282.89 |
| 4.00 | 3.00 | -10.00 | -11.00 | -5.00 | 7.00 | 19.00 | 22.00 | 19.00 | – | 4.00 | 9.00 | 20.00 | 26.00 | 33.00 | 43.00 |
| 5.56 | 4.29 | -14.08 | -15.71 | -6.49 | 6.86 | 16.67 | 17.32 | 14.29 | – | 3.10 | 6.34 | 12.50 | 14.44 | 5.46 | 6.42 |
| – | – | -12.00 | -11.00 | -6.00 | 6.00 | 22.00 | 22.00 | 17.00 | -2.00 | -2.00 | 8.00 | 14.00 | 20.00 | 27.00 | 35.00 |
| – | – | – | -8.33 | -45.45 | -200.00 | 266.67 | – | -22.73 | -111.76 | – | -500.00 | 75.00 | 42.86 | 35.00 | 29.63 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 0.20 | 0.42 | 0.50 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 110.00 | 19.05 |
| 28.77 | 36.18 | 38.66 | 36.42 | 36.46 | 40.33 | 40.33 | 41.25 | 40.73 | 45.54 | 44.83 | 57.48 | 54.40 | 61.66 | 61.66 | 61.66 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Kamada generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Kamada retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Kamada's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Kamada has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Kamada's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Kamada stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Kamada Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Kamada business model & stock analysis
Kamada SWOT Analysis
Strengths
Kamada Ltd has several key strengths that contribute to its success in the market. These strengths include:
- Strong brand recognition and reputation
- Robust product portfolio with a focus on high-quality medical solutions
- Established distribution channels and strategic partnerships
- Advanced research and development capabilities
- Global presence and market reach
Weaknesses
Despite its strengths, Kamada Ltd also has some weaknesses that it needs to address in order to maintain its competitive position:
- Reliance on a limited number of key suppliers
- Higher production costs compared to some competitors
- Dependence on regulatory approvals and compliance
- Limited diversification in product offerings
- Product recall risks
Opportunities
There are various opportunities available for Kamada Ltd to further expand its business and drive growth:
- Increasing demand for innovative medical solutions globally
- Emerging markets with untapped potential
- Advancements in technology driving new product development
- Collaboration opportunities with research institutions and healthcare providers
- Expansion into new therapeutic areas
Threats
Kamada Ltd faces certain threats that could potentially impact its performance and market position:
- Intense competition from established and emerging players
- Regulatory challenges and changing healthcare policies
- Volatility in raw material prices
- Economic uncertainties affecting healthcare spending
- Intellectual property infringement risks
Kamada Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Kamada Segments
Kamada Revenue by Segment
3 Years
Max
Details
Kamada Revenue by Region
3 Years
Max
Details
Kamada Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Kamada historical P/E ratio, EBIT multiple, and P/S ratio
Kamada annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Kamada's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Kamada's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Kamada's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Kamada shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Kamada Dividend History
2 years of dividend payments
Kamada dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Kamada dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Kamada forecasts and price targets in September 2026
Analyst Price Targets 2026Kamada Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 12/9/2025 | Maintained | Buy | – | |
| 5/15/2025 | Maintained | Buy | 76 | |
| 3/6/2025 | Maintained | Buy | – | |
| 1/10/2025 | Maintained | Buy | – | |
| 11/14/2024 | Maintained | Buy | – | |
| 8/15/2024 | Maintained | Buy | – | |
| 5/9/2024 | Maintained | Buy | – | |
| 3/7/2024 | Maintained | Buy | – | |
| 11/14/2023 | Maintained | Buy | – | |
| 8/17/2023 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Kamada Earnings Calls
Kamada Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/19/2026 | 0.11USD | - | 51.67 MUSD | - | 2026 Q2 |
| 5/13/2026 | 0.12USD | - | 47.66 MUSD | - | 2026 Q1 |
| 3/18/2026 | 0.08USD | - | 46.33 MUSD | - | 2025 Q4 |
| 8/12/2025 | 0.09USD | - | 45.56 MUSD | - | 2025 Q2 |
| 11/13/2024 | 0.07USD | - | 41.74 MUSD | - | 2024 Q3 |
| 3/13/2024 | 0.06USD | - | 38.46 MUSD | - | 2023 Q4 |
| 3/13/2023 | 0.01USD | - | 47.08 MUSD | - | 2022 Q4 |
| 11/22/2022 | -0.03USD | - | 30.20 MUSD | - | 2022 Q3 |
| 8/19/2022 | -0.02USD | -0.09USD | 23.94 MUSD | - | 2022 Q2 |
| 5/17/2022 | 0.03USD | -0.04USD | 32.91 MUSD | - | 2022 Q1 |
Kamada shareholder structure
| % | Name |
|---|---|
2.86920% | |
1.44245% | |
1.05837% | |
0.72843% | |
0.57161% | |
0.56143% |
Kamada Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
8.42% | SEC ↗ | |
8.35% | SEC ↗ | |
8.35% | SEC ↗ | |
8.15% | SEC ↗ | |
7.72% | SEC ↗ | |
7.56% | SEC ↗ | |
5.00% | SEC ↗ | |
5.00% | SEC ↗ | |
5.00% | SEC ↗ | |
5.00% | SEC ↗ |
Kamada Executives and Management Board
26 members · avg. age 60 · 38 % women
Dr. Ruth Wolfson (69)
Senior Vice President - Scientific Affairs
619,000.00 USD
Management
Mr. Amir London (47)
Chief Executive Officer
Mr. Chaime Orlev (51)
Chief Financial Officer
Mr. Barak Bashari (51)
Vice President - Operations
Mr. Nir Livneh
Vice President, General Counsel, Company Secretary
Ms. Shani Dotan (42)
Vice President - Human Resources
Ms. Yael Brenner (53)
Vice President - Quality
Board of Directors
Mr. David Tsur (73)
Deputy Chairman of the Board · since 2015
Ms. Lilach Asher Topilsky
Chairman of the Board · since 2020
Dr. Michael Berelowitz (77)
Director
Jonathan Hahn (33)
Director
Dr. Itzhak Krinsky (69)
Director
Ms. Gwen Melincoff (71)
Director
Frequently asked questions about Kamada
The business model of Kamada Ltd revolves around the development, production, and commercialization of specialty plasma-derived protein therapeutics. Kamada focuses on three main areas: respiratory diseases, AAT Deficiency, and graft-versus-host disease. By utilizing advanced technologies and expertise in protein purification, Kamada aims to provide innovative solutions for patients and healthcare professionals. With its comprehensive portfolio of FDA-approved products and strategic partnerships, Kamada strives to improve the quality of life for individuals facing these medical conditions. As a leading biopharmaceutical company, Kamada Ltd leverages its extensive knowledge and resources to bring transformative therapies to the market.
Kamada Ltd is primarily active in the biopharmaceutical industry.
The main competitors of Kamada Ltd in the market are companies like Takeda Pharmaceutical Company Limited, CSL Limited, and Grifols, S.A. These companies also operate in the biopharmaceutical industry and offer similar products and services. However, Kamada Ltd distinguishes itself through its innovative research and development efforts, strong global presence, and a diverse product portfolio. Its commitment to technological advancements and strategic partnerships enables Kamada Ltd to stay competitive and maintain a significant market position.
Kamada Ltd is a pharmaceutical company based in Israel. Founded in 1990, the company specializes in the development and production of plasma-derived protein therapeutics. With a focus on rare diseases and respiratory conditions, Kamada's innovative therapies have gained recognition globally. The company has a strong track record of successful partnerships with leading pharmaceutical companies and has expanded its market reach across Europe, the United States, and other regions. Kamada's dedication to research and development has resulted in numerous approvals from regulatory authorities, enhancing its reputation as a leader in the biopharmaceutical industry. Through its commitment to providing life-saving treatments, Kamada Ltd continues to improve the well-being of patients worldwide.
Kamada Ltd has achieved several significant milestones throughout its operation. The company demonstrated its dedication to innovation and development by receiving approval for several therapeutic products. For instance, in 2011, Kamada obtained FDA approval for Glassia, its flagship treatment for Alpha-1 Antitrypsin Deficiency. Additionally, the company successfully launched AATscan, a diagnostic tool used for detecting the presence of Alpha-1 Antitrypsin Deficiency. Furthermore, Kamada established partnerships with renowned global pharmaceutical companies, expanding its market presence and enhancing its research and development capabilities. These accomplishments highlight Kamada Ltd's commitment to advancing medical solutions and solidify their position as a leading player in the healthcare industry.
Kamada Ltd is primarily present in multiple countries and regions worldwide. With a strong global presence, the company operates in various key markets, including the United States, Canada, Europe, Israel, and Latin America. Kamada Ltd's diversified geographical footprint enables it to reach a wide range of customers and expand its distribution network effectively.
Kamada Ltd represents values of innovation, dedication, and excellence. Committed to improving patients' lives, Kamada focuses on developing and commercializing plasma-derived protein therapeutics. With a corporate philosophy centered on integrity, transparency, and ethical conduct, the company aims to deliver high-quality treatments and meet the medical needs of diverse patient populations. By prioritizing research and development initiatives, Kamada strives to leverage its scientific expertise and technological advancements to address unmet medical needs. Through collaboration and partnership, Kamada Ltd is dedicated to making a positive impact in the healthcare industry, promoting patient well-being, and advancing medical advancements.
Analysts currently set an average price target of 13.00 USD for the Kamada stock (median: 13.00 USD), implying +56.4 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Kamada stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Kamada to generate revenue of 604.36 M USD and earnings per share of 0.45 USD.
Converted at the current exchange rate, the Kamada share trades at 7.19 EUR (8.31 USD).
The Kamada share (KMDA) is listed on 2 stock exchanges, including: NASDAQ (KMDA).
Kamada Ltd. is a biopharmaceutical company based in Israel that specializes in the development, manufacturing, and marketing of products for the treatment of various diseases. The company's business model is based on its ability to produce innovative products based on proteins that are relevant for the therapy of diseases such as Alpha-1 antit... The company's main areas of focus include the production of intravenous immunoglobulins (IVIG) for the treatment of severe immunodeficiency disorders. IVIG is also used in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus. Kamada is currently the only manufacturer of IVIG in Israel. The company's products are also available in Europe and the USA. Another important area of the company is the production of alpha-1 proteinase inhibitors (AAT) for the treatment of alpha-1 antitrypsin deficiency. This is an inherited disease that can lead to severe lung damage. Kamada has introduced the first AAT product manufactured in Israel to the market. It is also distributed in Europe and the USA. In addition to IVIG and AAT, Kamada also produces Factor VIII concentrates for the treatment of hemophilia and for blood clotting in patients who have received blood transfusions. The company also manufactures enzymes for the diagnosis of diseases and for research. Another business area of the company is the development of biosimilars, which mimic biological medicines that are already on the market. Kamada's biosimilars will help improve access to important therapies and relieve healthcare systems. Currently, the company is developing biosimilars for use in lung diseases and malignant diseases. Kamada's business model also includes collaboration with other companies in the biotechnology industry. The company has partnerships with leading companies such as Baxter, Shire, and Novartis to distribute or co-develop its products. In summary, Kamada's business model is focused on producing and marketing innovative products for the treatment of various diseases. The company specializes in protein production and has partnerships with other biotechnology companies. The different divisions of the company include the production of IVIG, AAT, Factor VIII concentrates, enzymes, and biosimilars. Kamada is also involved in the development of new products to meet patient needs and improve access to important therapies.
The expected revenue of Kamada is 604.36 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Kamada is 27.50 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Kamada is currently 18.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Kamada stock.
The price-to-sales ratio (P/S) of Kamada is currently 0.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Kamada stock.
The Eulerpool Quality Score for Kamada is 5/10.
The ISIN of Kamada is IL0010941198. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Kamada is A0JMEX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Kamada is KMDA. The ticker symbol is used to trade Kamada shares on the stock exchange.
Over the past 12 months, Kamada paid a dividend of 0.20 USD . This corresponds to a dividend yield of about 2.41 %. For the coming 12 months, Kamada is expected to pay a dividend of 0.50 USD.
The current dividend yield of Kamada is 2.41 %.
Kamada paid dividends every year for the past 1 years.
For the upcoming 12 months, dividends amounting to 0.50 USD are expected. This corresponds to a dividend yield of 6.06 %.
Kamada is assigned to the 'Health' sector.
To receive the latest dividend of Kamada from 9/17/2026 amounting to 0.17 USD, you needed to have the stock in your portfolio before the ex-date on 8/27/2026.
The last dividend was paid out on 9/17/2026.
In the year 2025, Kamada distributed 0.2 USD as dividends.
The dividends of Kamada are distributed in USD.
Kamada stock
Kamada Peer Group
Kamada Ticker
Kamada FIGI
All fundamentals and in-depth analysis of Kamada
Our stock analysis for Kamada stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kamada. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.